The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.
"In the triple class refractory group of patients, we do have limited choices. Of the agents that we have, the typical median PFS and DOR are much less than what we've seen so far with cilta-cel, so I do think that it's going to offer the ability for some of these relapsed refractory myeloma patients to live longer and to have better quality of life."
Ciltacabtagene autoleucel (cilta-cel) has continued to produce deep and durable responses in heavily-pretreated patients with multiple myeloma, according to findings from the phase 1/2 CARTITUDE-1 study (NCT03548207).1,2
Further data on cilta-cel's potential as an earlier line of therapy has been demonstrated in the phase 2 CARTITUDE-2 study (NCT04133636).3 During this study, investigators found that progression-free survival (PFS) at 6 months was 90% (95% CI, 65.6–97.4) in patients with multiple myeloma and only 1 to 3 prior lines of therapy.
CGTLive spoke with investigator Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California San Francisco, and co-leader, Cancer Immunology & Immunotherapy Program, Helen Diller Family Comprehensive Cancer CenterMartin to learn more about the challenges in treating patients with refractory multiple myeloma. He discussed other exciting cell therapies in the space that will be advancing in 2022.
(Editor’s note: cilta-cel was approved for the treatment of adult patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy on February 28, 2022.)